Furthermore, in a recent publication, a Breakthrough T1D-led perspective outlined a significant body of evidence from 3 datasets demonstrating that even small amounts of preserved endogenous insulin production, assessed as C-peptide in people with T1D are linked to better clinical outcomes, including lower HbA1c, decreased risk of hypoglycemia, neuropathy, and retinopathy (3). This evidence concerns the gene INS and type 1 diabetes mellitus.